

SABINSA NEWS RELEASE

Sabinsa Korea to showcase the Safety and Efficacy of Shelf-Stable LactoSpore™ at the Probiotic Symposium in Seoul, Korea

Seoul, Korea (May 21, 2024) – Sabinsa, the globally renowned research-oriented supplier known for its sustainable and innovative nutraceutical and cosmeceutical ingredients, will highlight LactoSpore™ *Weizmannia coagulans* at the Expanding the Lineup: Next Probiotics and Supplement Spring Symposium hosted by the Korean Society for Lactic Acid Bacteria and Probiotics in Seoul, Korea on May 24, 2024.

“LactoSpore is a successful product worldwide, but especially in markets such as South Korea where customers have a higher understanding of probiotics,” said Mr. Shaheen Majeed, Global Managing Director and CEO of Sabinsa. “Because of its efficacy, safety, and flexibility in a range of manufacturing conditions, LactoSpore is formulated into numerous product categories from supplements to functional foods.”

Dr. Sivakumar Arumugam, Vice President, Biotechnology, Sami-Sabinsa Group, will deliver a presentation on “Safety and efficacy of *Weizmannia coagulans*, a spore forming and shelf-stable probiotic, for gut health and beyond” in the International Conference Room, Konkuk University, Seoul, on May 24, 4:30 p.m. to 5:00 p.m.

Sabinsa’s LactoSpore *Weizmannia coagulans*, MTCC 5856 (previously known as *Bacillus coagulans*), has been a popular probiotic on the global market since the early 1990’s. Its safety and efficacy demonstrated by clinical studies, coupled with its stability at room temperature and ability to withstand challenging manufacturing conditions, have made it a probiotic of choice among dietary supplement and functional food manufacturers worldwide.

LactoSpore’s lactic acid-producing bacteria form spores, or seeds. When activated in the GI Tract, the spores germinate and proliferate in the intestine, producing the favored form of lactic acid that prevents the growth of pathogens, helping maintain a balanced gut microbiome. These spores are extremely stable, remaining dormant until they arrive safely in the intestinal tract to colonize and grow. Spore forming allows *Weizmannia coagulans* to survive at both high and low temperatures, and resist the harsh human gastric environment, enabling delivery under a wide range of conditions and through a broad spectrum of systems.

The most recent recognition of LactoSpore’s superiority was the 2023 Technology Innovation Award at the 3rd Food Formula Innovation Show held in China. Sabinsa’s LactoSpore currently holds 38 granted active patents across the globe.

For more information, visit www.sabinsa.co.kr or www.sami-sabinsagroup.com.

Note: LactoSpore™, a Trademark of Sabinsa Korea Corporation.

About Sabinsa

Sabinsa, founded by the late Dr. Muhammed Majeed in 1988, is a manufacturer and supplier of standardized herbal extracts, nutraceutical and cosmeceutical ingredients, probiotics, minerals, enzymes, and specialty and fine chemicals. The company markets over 120 standardized botanical extracts and employs more than 1,400 people worldwide in 27 manufacturing, R&D, sales, and distribution facilities. Process development and product innovation form the focus of the ongoing R&D efforts in the company's research facilities, located in India and the U.S. Products, many of which are both Kosher and Halal, are extensively researched, patented, and supported by hundreds of published clinical studies. Sabinsa's botanical cultivation program totals nearly 20,000 acres to ensure sustainable, fair-trade materials are used in these ingredients. For more information, visit sabinsa.com or www.sami-sabinsagroup.com.

Media Contact

Suzanne Shelton - The Shelton Group

Suzanne@SheltonGroupPR.com Cell: +1 847-922-5454